Careers  |  Sign In  |  Register

Leukemia Drug, Iclusig Under Federal Investigation

Ariad Pharmaceuticals Inc. (ARIA)’s leukemia drug Iclusig is now under investigation by healthcare officials due to increasing frequency of blood clots and narrowing of the major arteries. The drug was approved last year under an “accelerated process” for the treatment of two rare forms of leukemia. While Ariad drew in $14 million in its first quarter, its sales have plunged a record 66% since October 9th. Patients taking the drug have also experienced side effects such as heart attack, stroke, and narrowing of the large arteries of the brain. The FDA urges doctor to consider, “whether the benefits of Iclusig treatment are likely to exceed the risks of treatment.”

Read the article published by Bloomberg News.